MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received a drug license suspension order for one of its stores in Chhattisgarh. The disclosure was made pursuant to Regulation 30 read with Para A, Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with relevant SEBI circulars.

Drug License Suspension Order Details

The suspension order was issued by the Assistant Drugs Controller, Durg District, Chhattisgarh, targeting the store situated at Santrabadi Durg, Chhattisgarh. The order was received on May 05, 2026, and mandates a suspension of the drug license for a period of sixty-five days. The action has been initiated under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

The following table summarises the key details of the regulatory action as disclosed by the company:

Financial and Operational Impact

The company has quantified the potential financial impact of this suspension at Rs 16.00 lacs in revenue loss. The affected store is operated by Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services. The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on May 06, 2026.

The regulatory filing is available on the company's website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited.

MedPlus Health Services Limited has announced a revised schedule for its board meeting to approve the audited financial results for the fourth quarter and full financial year 2026. The pharmaceutical retail chain issued the updated intimation on May 3, 2026, referencing an earlier communication dated March 28, 2026.

Board Meeting Schedule

The company's board of directors will convene on May 20, 2026, to consider and approve both standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.

Regulatory Compliance and Trading Window

In adherence to SEBI regulations, MedPlus has implemented a trading window closure for designated persons and their immediate relatives. The restriction period spans from April 1, 2026, to May 22, 2026, both days inclusive, extending 48 hours beyond the financial results declaration.

Results Dissemination

Following the board meeting's conclusion, the approved financial results will be submitted to both BSE Limited and National Stock Exchange of India Limited. The company will also publish the results in newspapers as mandated by SEBI LODR Regulations, 2015.

The financial results and related documents will be made available on multiple platforms including the company's official website at www.medplusindia.com , BSE's website at www.bseindia.com , and NSE's website at www.nseindia.com .

Corporate Communication

The revised intimation was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer, ensuring proper regulatory compliance and stakeholder communication. This revision demonstrates the company's commitment to transparent disclosure practices and adherence to stock exchange requirements.